In addition, it has been reported that statin treatment increases the vulnerability of PGC1α-suppressed BRAF-inhibitor resistant melanomas [42], and it may be effective against melanomas that gradually develop resistance to vemurafenib. This evidence concerns the gene PPARGC1A and melanoma.